BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 11963634)

  • 21. Angiotensin II receptor blockade and end-organ protection: pharmacological rationale and evidence.
    Unger T; Culman J; Gohlke P
    J Hypertens Suppl; 1998 Sep; 16(7):S3-9. PubMed ID: 9855025
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evidence for renoprotection by blockade of the renin-angiotensin-aldosterone system in hypertension and diabetes.
    Karalliedde J; Viberti G
    J Hum Hypertens; 2006 Apr; 20(4):239-53. PubMed ID: 16452996
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Comparison of angiotensin receptor antagonists and angiotensin converting enzyme inhibitors in arterial hypertension].
    Krezsinski JM; Sternon J
    Rev Med Brux; 2000 Jun; 21(3):170-7. PubMed ID: 10925600
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Prevention of type 2 diabetes mellitus due to antihypertensive treatment affecting renin-angiotensin system].
    Boucek P
    Vnitr Lek; 2006 Sep; 52(9):791-6. PubMed ID: 17091602
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of angiotensin II receptors and their antagonists in hypertension.
    van Zwieten PA
    Ann Ital Med Int; 2000; 15(1):85-91. PubMed ID: 10842896
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting mechanisms of hypertensive vascular disease with dual calcium channel and renin-angiotensin system blockade.
    Weir MR
    J Hum Hypertens; 2007 Oct; 21(10):770-9. PubMed ID: 17597800
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Renin-angiotensin-aldosterone system blockade and renal protection: angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers?
    Ruilope LM
    Acta Diabetol; 2005 Apr; 42 Suppl 1():S33-41. PubMed ID: 15868118
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of the renin-angiotensin system and target organ protection.
    Iwanami J; Mogi M; Iwai M; Horiuchi M
    Hypertens Res; 2009 Apr; 32(4):229-37. PubMed ID: 19262496
    [TBL] [Abstract][Full Text] [Related]  

  • 29. RAS inhibition in hypertension.
    Ibrahim MM
    J Hum Hypertens; 2006 Feb; 20(2):101-8. PubMed ID: 16397519
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibitors of the renin-angiotensin system.
    Brunner HR; Nussberger J; Waeber B
    Arzneimittelforschung; 1993 Feb; 43(2A):274-8. PubMed ID: 8498978
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Pathophysiological and clinical implications of AT(1) and AT(2) angiotensin II receptors in essential hypertension].
    Burnier M
    Drugs; 2002; 62 Spec No 1():21-9. PubMed ID: 12036386
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fetopathy associated with exposure to angiotensin converting enzyme inhibitors and angiotensin receptor antagonists.
    Quan A
    Early Hum Dev; 2006 Jan; 82(1):23-8. PubMed ID: 16427219
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Are all antihypertensive drugs renoprotective?].
    Wolf S; Risler T
    Herz; 2004 May; 29(3):248-54. PubMed ID: 15167950
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antihypertensive strategy based on angiotensin II receptor blockers: a new gateway to reduce risk in hypertension.
    Tocci G; Sciarretta S; Facciolo C; Volpe M
    Expert Rev Cardiovasc Ther; 2007 Jul; 5(4):767-76. PubMed ID: 17605654
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New opportunities in cardiovascular patient management: a survey of clinical data on the combination of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Weber MA
    Am J Cardiol; 2007 Aug; 100(3A):45J-52J. PubMed ID: 17666198
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Antihypertensive treatment for patients with hypertension and diabetes type II--current clinical research].
    Rajzer M; Kawecka-Jaszcz K; Wojciechowska W
    Przegl Lek; 2003; 60(2):111-5. PubMed ID: 12939858
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
    Horký K
    Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An update on non-peptide angiotensin receptor antagonists and related RAAS modulators.
    Aulakh GK; Sodhi RK; Singh M
    Life Sci; 2007 Aug; 81(8):615-39. PubMed ID: 17692338
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The renin system: is direct renin inhibition different from blockade at the AT1 receptor or the ACE step?
    Hollenberg NK
    Rev Cardiovasc Med; 2007; 8 Suppl 2():S7-13. PubMed ID: 17401314
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Renin inhibitors: novel agents for renoprotection or a better angiotensin receptor blocker for blood pressure lowering?
    Weir MR
    Curr Opin Nephrol Hypertens; 2007 Sep; 16(5):416-21. PubMed ID: 17693755
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.